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Background: Systemic inflammatory response frequently
occurs after coronary artery bypass surgery and is strongly
correlated with the risk of postoperative morbidity and
mortality. This study tests the hypothesis that the priming
of the extracorporeal circuit with colloid solutions results
in less inflammation in patients undergoing cardiac sur-
gery than priming with crystalloid solutions.
Methods: A prospective, randomized study was designed.
Forty-four patients undergoing elective coronary artery
bypass grafting were randomly allocated to one of two
groups: 22 patients primed with Ringer ’s lactate (RL)
solution and 22 patients primed with gelatin-containing
solution during the surgery. Plasma levels of interleukin
(IL)-6, IL-8, tumor necrosis factor (TNF)-a, C-reactive
protein (CRP) and, complement 4 were measured during
the surgical intervention and over the following 48
postoperative hours. Cytokine levels were measured by
enzyme-linked assays from plasma samples obtained at
specific time points pre- and post-operatively.
Results: In both groups the serum levels of the pro-inflamma-
tory cytokines (IL-6, IL-8, TNF-a), CRP, complement 4, and
leukocytes increased significantly over the baseline, although no
significant differences were observed between the two groups.
The operation time, blood loss, need for inotropic support,
extubation time, and length of intensive care unit stay did not
differ significantly between the two groups.
Conclusion: Priming with gelatin vs. RL produces no
significant differences in the inflammatory response in
patients undergoing coronary artery bypass grafting with
cardiopulmonary bypass.
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CARDIOPULMONARY bypass (CPB) has been asso-ciated, during surgery and in the early post-
operative stage, with a large variety of clinical
symptoms, including haemodynamic instability
(hypotension, vasodilatation), fever, bleeding dis-
orders, and organ dysfunction in severe cases.1 It
has been suggested that these effects are symp-
toms of a systemic inflammatory response syn-
drome (SIRS) resulting from extensive cellular
activation, likely caused both by the contact of
blood with the foreign material of the extracor-
poreal circuit and by trauma induced by surgery.
This response is mediated by the release of pro-
inflammatory cytokines, especially interleukin
(IL)-6, IL-8, and tumor necrosis factor-a (TNF-
a).2–3 Because the extent of SIRS is strongly corre-
lated with the risk of postoperative morbidity,
efforts to reduce SIRS activation are of potential
clinical importance.
Prevention of the inflammatory response due to
CPB has been attempted using different perfusion
techniques (oxygenator, cardioplegia, biocompat-
ibility of CPB setups) and pharmacological agents
(corticosteroids, aprotinin). The composition of the
solution used to prime the extracorporeal circuit
causes a modulation of the neutrophil complement
activation and repercussions in the inflammatory
response as well as a modulation in blood levels of
inflammatory mediators (cytokines).4–6A recent
study evaluated the effect of priming the extracor-
poreal circuit with crytalloid alone, crystalloid plus
albumin, or crystalloid plus the plasma expanding
polygelatin on complement activation, and the
results indicated that the addition of polygelatin
to the priming solution reduces complement activa-
tion.5 Cavarocchi et al.7 reported significantly less
complement activation with a prime containing
12.55 vol/5% albumin. Other reports suggest that
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priming of extracorporeal circulation with crystal-
loid (Hartman solutions) may cause an increase in
plasma water content8 and marked activation of the
neutrophil as compared with albumin.4
Together this suggests that the use of crystalloid
solutions in the priming of the CPB appears to
contribute to greater activation of both neutrophil
and complement. Here we test the hypothesis that
priming the volume of the extracorporeal circuit
with colloid rather than crystalloid solutions results
in reduced inflammation [lower cytokine, comple-
ment, C-reactive protein (CRP), and leukocyte
levels in the blood], thus reducing patient morbidity.
We compared the effects of gelatin priming vs.
Ringer’s lactate (RL) priming on cytokine release
and during the inflammatory state following cor-
onary artery bypass surgery with CPB. We also
examined the relationships between cytokines,
CRP, and complement levels with postoperative
variables at specific time points (respiratory insuf-
ficiency, PaO2/FIO2 ratio, etc.).
Materials and methods
Study protocol
Patients scheduled to undergo elective coronary
artery bypass graft surgery at our centre were
evaluated for possible inclusion in the study. Pa-
tients with renal or hepatic impairment, congestive
heart failure, severely impaired left ventricular
function (ejection fractiono40%), active inflamma-
tory/immunomodulatory diseases, a history of
myocardial infarction o6 months previously, and
those who had pre-operative use of steroids were
excluded. Patients undergoing urgent surgery or
repeated surgical interventions were also excluded.
Cardiac medications including b-adrenergic block-
ing agents, calcium-channel blocking agents, and
nitrates were continued until the surgery.
A computerized table of aleatory numbers was
used to randomize allocation. Forty-four subjects
who fulfilled the inclusion criteria were randomly
allocated to one of two groups during CPB: the RL
(RL; B. Braun, Melsungen, Germany) prime (RL
group, 22 patients) or the gelatin (Gelofusine, B.
Braun, Melsungen, Germany) containing prime
(GEL group, 22 patients). Except for the perfusionists,
the clinical team was blinded to the randomization.
The study protocol was approved by the ethics
committee of the ‘Clinico’ Hospital of Valladolid.
Written informed consent was obtained from each
patient.
Operative procedure and postoperative care
All patients underwent coronary bypass surgery
with CPB using standard procedures. All patients
were premedicated during the night with oral fluni-
tracepam 2 mg, and 5 mg of morphine was injected
on the morning of the intervention. Arterial pressure,
pulse pressure, and EKG were monitored in the
operating theatre. A 20-G catheter was then inserted
into the radial artery and the internal jugular vein.
Anaesthesia was induced in all patients [0.1 mg/kg
intravenous (i.v.) midazolam, 5–10mg/kg i.v. fenta-
nyl, followed by 2–5 mg/kg i.v. thiopental] and
tracheal intubation was facilitated with 1 mg/kg i.v.
rocuronium. After tracheal intubation, the lungs
were ventilated to normocapnia using an oxygen–
air mixture (intake oxygen fraction 0.5). Mechanical
ventilation was carried out using an anaesthesia
machine, model Datex-Ohmeda S/5 Aespire 3000
(Datex-Ohmeda Ltd., Madson, WI) with controlled
ventilation. Anaesthesia was maintained using se-
vorane 0.5–1.5%, fentanyl 3mg/kg/h, and rocuro-
nium 0.3 mg/kg/h. The inspired sevoflurane
concentration was varied to maintain the mean
arterial pressure (MAP) within 20% of the preinduc-
tion baseline values.
The extracorporeal circulation system consisted of
a soft-shell venous reservoir, roller pump, and mem-
brane oxygenator (D903 AVANT with integrated
biocompatible circuit covered by phosphorylchlorine
inert surface; DIDECO, Mirandola, Italy). In all cases,
the extracorporeal circuit was primed with 1750 ml.
The crystalloid prime solution contained lactated
Ringer’s solution 1500 ml, 20% mannitol 100 ml,
aprotinin 100 ml, 8.4% sodium bicarbonate 50 ml,
and heparin 5000 IU. The colloid prime solution
contained gelatin 1000 ml, lactated Ringer’s solution
500 ml, 20% mannitol 100 ml, aprotinin 100 ml, 8.4%
sodium bicarbonate 50 ml, and heparin 5000 IU.
The heart was exposed through a median ster-
notomy. To perform sub-total CPB, a standard can-
nulation was performed with the cannule placed in
the ascending aorta and the right atrium. After
systemic heparinization (300 IE/kg), CPB com-
menced under the condition that the activated clot-
ting time was more than 400 s. The left ventricle was
vented via the aortic root. Blood from the pericardial
cavity was collected in a cardiotomy reservoir and
returned to the patient. The haematocrit value was
maintained between 20% and 25%, and pump flows
were kept between 2.0 and 2.5 l/min/m2 to main-
tain MAP between 50 and 70 mmHg. If arterial
pressure declined below 50 mmHg, flow rate
increased, and vasoactive drugs were given. All
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patients were cooled to moderate hypothermia
(mean 32 1C nasopharyngeal temperature). After
aortic cross-clamping, all patients received crystalloid
cardioplegia for myocardial protection (800–1000 ml,
potassium 16 ml/l, 4 1C). Acid–base balance was
managed following the a-stat concept. Patients
were weaned from CPB using inotropic support if
necessary. After termination of CPB, heparin was
neutralized using an equivalent dose of protamine
sulphate 3 mg/kg guided by low filling pressures of
0.9% NaCl and gelatin was additionally infused.
At the end of surgery, patients were transferred
to the intensive care unit (ICU), where they were
treated according to a standard regimen. Haemo-
dynamic values were assessed at a heart rate (HR)
of 70–80 beat/min and a MAP of 65–80 mmHg.
Inotropic support depended on the individual
status of the patient. Basic i.v. fluid administration
consisted of 0.9% NaCl and gelatin was infused.
Fluid balance, rectal temperature, and peripheral
temperature (measured on the back of the foot)
were recorded every hour. The peripheral circula-
tion (DT) was considered to be adequate if the
difference between rectal temperature and periph-
eral skin temperature was o5 1C. The lungs were
ventilated with 60% oxygen using volume-con-
trolled ventilation (Servo Ventilator 900C; Siemens,
Stockholm, Sweden) and a tidal volume of 10 ml/
kg with 5 cmH2O of positive end-expiratory pres-
sure. Analysis of arterial blood gas was conducted
by standard techniques using an automated analy-
ser and anaesthesia induction at 4-h intervals for
24 h after termination of CPB. All patients were
extubated in the ICU when the Tobin index [re-
spiratory rate (spontaneous)/tidal volume (L)] was
o105,9,10 PaO2 was 460 mmHg, FIO2 was o0.4,
continuous positive airway pressure was o5 mbr,
PaCO2 was 50 mmHg, and arterial pH was 47.35.
PaO2/FIO2.
Intra-operative data
Intra-operative variables, including CPB time, aor-
tic cross-clamp time, the need for inotropic sup-
port, volume administered during CPB, lowest
rectal temperature, urinary output, and the number
of aortocoronary bypass grafts, were analysed and
recorded (Tables 1 and 2).
Haemodynamic measurements
MAP, HR, and central venous pressure (CVP) were
measured as haemodynamic indicators. Haemody-
namic evaluations were performed before the
Table 1
Demographics, clinical characteristics, and operative data.
Variable Total n5 44 RL n5 22 GEL n5 22 P-value
Age, years 67  7.5 66.50  6.9 67.8  8.1 0.567
Male gender [n (%)] 36 (82) 17 (77) 19 (86) 0.696
Current smoker [n (%)] 16 (36) 9 (41) 7 (32) 0.530
Diabetes mellitus [n (%)] 15 (34) 6 (27) 9 (41) 0.526
Hypertension [n (%)] 19 (43) 8 (36) 11 (50) 0.361
NYHA class [n (%)]
I 1 (2) 1 (4) 0 (0) 0.311
II 36 (82) 17 (77) 19 (86) 0.434
III 4 (9) 1 (4) 3 (13) 0.294
Additional drugs, n (%)
b-blockers 15 (34.1) 7 (31.8) 8 (36.4) 0.750
Ca21 channel blockers 13 (30.1) 5 (22.7) 8 (36.4) 0.321
Nitrates 29 (65.9) 12 (54.5) 17 (77.3) 0.551
Ejection fraction (%) 61.9  10.7 63.22  10.8 60.59  10.8 0.872
Creatinine (mg/dl) 0.9  0.6 1.07  0.7 0.88  0.5 0.328
Total CPB time, min 101.3  24.3 100.5  25.9 102.1  23.2 0.277
Aortic cross-clamp, min 65.6  17.8 63.3  19.6 68.0  15.9 0.391
Number of grafts 3.18  0.76 3.23  0.75 3.14  0.77 0.695
Fluid in the operating room, ml 2451.1  468.0 2577.3  434.2 2325.0  476.0 0.073
PaO2/FIO2 base 320.7  115.6 322.5  134.3 318.9  96.6 0.919
PaO2/FIO2 before-CPB 331.4  92.8 366.3  68.6 296.5  101.8 0.011*
PaO2/FIO2 end-CPB 298.3  140.0 283.2  136.2 313.5  145.4 0.480
Values are expressed as numbers (n), percentages (%), and means  SD.
*Probability value of Po0.05 was considered to be significant.
RL, Ringer’s lactate; GEL, gelatin; NYHA, New York Heart Association; CPB, cardiopulmonary bypass; Base, before the operation;
Before-CPB, before the cardiopulmonary bypass; End-CPB, at the end of cardiopulmonary bypass.
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operation (base), before the CPB (before-CPB), at the
end of the CPB (end-CPB), on arrival in the ICU (1 h-
ICU), and at 6 h (6 h-ICU), 24 h (24 h-ICU), and 48 h
(48 h-ICU) after surgery.
Blood sample collection, stocking, and analysis
Blood specimens for haemoglobin, haematocrit,
white blood cell numbers, platelet counts, and
creatinine were collected in 5-ml glass Vacutainer
tubes containing EDTA (Becton Dickinson, Nor-
cross, GA). Blood samples for measuring the com-
plement (C4), CRP, and cytokine serum levels were
collected via a radial arterial catheter at the follow-
ing points: before the operation (base), before the
CPB (before-CPB), at the end of the CPB (end-CPB),
on arrival in the ICU (1 h-ICU), and at 6 h (6 h-ICU),
24 h (24 h-ICU), and 48 h (48 h-ICU) after surgery.
All blood samples were drawn in pre-chilled va-
cuum tubes containing EDTA. The samples were
immediately centrifuged at 4 1C and stored at
 80 1C until assayed. IL-6, IL-8, and TNF-a were
determined by ELISA as previously described.11
ILs were measured with an ELISA Kit (ELISA;
immulite 2000 for IL-6, inmunolite 1000 for IL-8,
and inmunolite 1000 for TNF-a DPG, Los Angeles,
CA). All assays were controlled according to the
manufacturer’s instructions. All samples were mea-
sured in duplicate. Concentrations were not cor-
rected for dilution. The arterial blood samples for
analysing gasometry, haemoglobin, haematocrit,
white blood cell numbers, platelet counts, and crea-
tinine and albumin were collected simultaneously.
Total C4, CRP, and albumin concentrations were
determined by nephelometry (Behring Diagnostics
Benelux NV; Behring Nephelometer Analyser,
Behringwerke AG, Marburg, Germany), according
to the manufacturer’s protocol.
Respiratory insufficiency12 was indicated by the
presence of arterial hypoxemia, defined as a PaO2/
FIO2 ratio o300, in any of the determinations.
Blood specimens were obtained for the analysis
of cardiac enzymes. Total serum activity of creati-
nine kinase (CK) was determined by the enzymatic
method, and the activity of MB isoenzyme creatine
kinase (CK-MB) was quantified by the immuno-
assay method. CK and CK-MB were evaluated at
the following intervals: on arrival in the ICU (1 h-
ICU), and at 6 h (6 h-ICU), 24 h (24 h-ICU), and 48 h
(48 h-ICU) after surgery.
Information regarding clinical, demographic,
treatment, and procedural factors, as well as hos-
pital outcome, was obtained prospectively using a
specialized case report form.
Statistical analysis
Before the study, the number of patients required in
each group was determined by a power calculation
according to data obtained from previous studies
on the release of IL-6 in the patients undergoing
cardiac surgery with CPB.6,8,13 We hypothesized
that purging with gelatin as compared with a RL
therapy regimen would reduce the IL-6 response
by 30%. A population of 40 patients (20 in each
group) would be needed to detect this difference
with an a of 0.05 and a power of 0.80.
Data are presented as mean ( SD). Values of
IL-6, IL-8, TNF-a, CRP, and complement (C4) are
represented as medians with interquartile range
unless otherwise stated. The SPSS program (ver-
sion 13) was used for statistical analysis of the data.
Raw data were analysed for normality of distribu-
tion. If not normally distributed, data were sub-
jected to log transformation before analysis. We
used Fisher’s exact test to compare categorical
Table 2
Postoperative haemodynamic.
Variable Group Base Before-CPB End-CPB 1h-ICU 6h-ICU 24h-ICU 48-h-ICU
HR, beats/min
RL group 86.4  15.4 80.8  23.6 87.0  15.0 88.2  15.7 82.2  10.4 88.2  8.8 85.8  11.1
GEL group 86.7  25.5 81.0  12.1 85.0  17.0 80.0  12.9 89.0  16.2 81.7  12.3 84.7  12.4
MAP, mmHg
RL group 76.6  9.1 78.0  13.1 73.0  18.7 86.6  16.4 85.0  10.5 85.8  11.1 79.8  6.9
GEL group 76.7  15.7 75.7  4.1 79.5  15.2 83.7  14.1 82.7  13.5 84.7  12.4 87.5  10.0
CVP, mmHg
RL group 4.0  1.5 2.6  1.5 2.8  1.3 2.8  1.3 5.8  4.6 8.0  3.1 9.0  2.2
GEL group 5.7  3.1 2.2  0.5 2.2  0.5 2.0  0.8 8.0  4.1 9.0  2.9 8.4  2.3
Values are expressed as mean  SD.
Base, before the operation; Before-CPB, before the cardiopulmonary bypass; End-CPB, at the end of cardiopulmonary bypass; 1 hr-
ICU, at arrival in the intensive care unit; 6h-ICU, 6h after surgery; 24 h-ICU, 24 h after surgery; 48 h-ICU, 48 h after surgery; HR, heart
rate; MAP, mean arterial pressure; CVP, central venous pressure; RL, Ringer’s lactate prime; GEL, gelatin prime.
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variables and Student’s t-tests to compare contin-
uous variables as appropriate. Differences from
baseline and between the groups were evaluated
by two-way analysis of variance for repeated mea-
surements (ANOVA), followed by Scheffe’s test.
Correlation analysis between variables was calcu-
lated using Pearson’s correlation coefficient.
A probability value of Po0.05 was considered
significant.
Results
Patients
Clinical and operative characteristics are shown in
Table 1. There were no significant differences be-
tween the groups regarding pre-operative data.
Patients were similar with regard to type of proce-
dure, bypass time, aortic cross-clamp time, and
number of grafts. The PaO2/FIO2 ratio before CPB
was less in the GEL group than in the RL group
(P5 0.011). No complications occurred and all
patients survived.
Haemodynamic function measurement
Repeated-measures ANOVA revealed that differ-
ences were not significant (P40.05) over time
within groups or between groups for HR, MAP,
and CVP measurements (Table 2).
Pre- and postoperative laboratory data
There were no significant inter-group differences in
the haemoglobin, haematocrit, platelet, leukocyte,
and albumin counts. The number of leukocytes in
both groups increased significantly on arrival in the
ICU (Po0.0001). Haemoglobin (before-CPB,
Po0.0001), haematocrit (before-CPB, Po0.0001),
platelet (before-CPB, Po0.0001), and albumin
(before-CPB, Po0.0001) counts were significantly
reduced in both groups as compared with the
baseline (Table 3).
The postoperative course
The postoperative course in the two groups
showed no significant difference in death, creati-
nine, respiratory insufficiency, PaO2/FIO2 ratio,
postoperative bleeding, extubation time, number
of patients extubated at 24 h, atrial fibrillation, CPK
and CPK-MB levels in blood, need for blood
transfusion, units of donor blood, need for inotro-
pic support, or length of ICU stay (Table 4). Neither
were there any differences between the groups Ta
bl
e
3
P
re
-
a
n
d
p
o
s
to
p
e
ra
ti
v
e
la
b
o
ra
to
ry
b
lo
o
d
s
a
m
p
le
a
n
a
ly
si
s
.
V
a
ri
a
b
le
g
ro
u
p
B
a
s
e
B
e
fo
re
-C
P
B
E
n
d
-C
P
B
1
h
-I
C
U
6
h
-I
C
U
2
4
h
-I
C
U
4
8
h
-I
C
U
H
e
m
o
g
lo
b
in
(m
g
/d
l)
R
L
g
ro
u
p
1
2
.9

2
.0
7
.6

1
.5
7
.8

0
.9
1
0
.0

1
.3
1
0
.8

1
.4
1
0
.6

1
.6
1
0
.8

1
.6
G
E
L
g
ro
u
p
1
1
.8

2
.0
7
.5

1
.4
7
.8

1
.2
1
0
.0

1
.4
1
1
.2

1
.2
1
1
.3

1
.2
1
1
.1

1
.4
H
a
e
m
a
to
c
ri
t
(%
)
R
L
g
ro
u
p
3
8
.7

5
.5
2
3
.
3

4
.4
2
3
.6

2
.6
3
0
.1

4
.4
3
2
.3

3
.6
3
1
.8

4
.4
3
2
.6

4
.3
G
E
L
g
ro
u
p
3
6
.5

5
.1
2
4
.1

4
.0
2
4
.9

3
.0
3
0
.5

4
.0
3
3
.9

3
.7
3
4
.1

3
.5
3
4
.0

4
.2
P
la
te
le
t/
(m
m
3
)
R
L
g
ro
u
p
1
8
0
.5
4
5

5
0
.2
2
0
1
4
1
.0
9
0

4
9
.2
1
2
1
1
7
.9
5
4

4
7
.0
3
3
1
1
5
.4
5
4

4
1
.7
1
2
1
3
1
.9
5
4

4
2
.6
5
6
1
3
1
.9
0
9

4
0
.1
0
5
1
3
5
.0
0
0

5
7
.3
5
6
G
E
L
g
ro
u
p
1
9
7
.1
8
1

4
3
.6
4
7
1
3
7
.5
0
0

5
2
.0
0
1
1
1
6
.3
1
8

4
6
.0
2
4
1
1
5
.2
2
7

4
3
.2
7
3
1
3
3
.7
2
7

5
2
.6
8
4
1
3
1
.1
3
6

5
1
.4
0
3
1
2
3
.3
6
3

4
4
.6
6
2
L
e
u
k
o
c
y
te
/(
m
m
3
)
R
L
g
ro
u
p
6
.8
1
9

2
.4
5
2
5
.6
9
5

2
.5
3
1
8
.9
1
8

3
.8
1
6
1
0
.1
5
2

3
.5
6
9
1
0
.3
8
9

3
.7
7
5
9
.7
1
4

3
.1
3
2
9
.3
3
5

3
.5
6
9
G
E
L
g
ro
u
p
6
.6
6
4

2
.2
0
3
5
.7
9
7

2
.4
3
0
1
0
.0
3
3

3
.5
8
8
1
1
.1
9
0

4
.0
8
2
1
1
.2
2
1

4
.5
9
9
9
.6
1
2

2
.6
5
8
9
.3
5
9

2
.8
6
5
A
lb
u
m
in
(g
/l
)
R
L
g
ro
u
p
3
3
.4
4
1

5
.7
4
3
2
0
.3
7
3

3
.0
7
8
2
1
.0
4
1

2
.9
4
0
2
4
.3
1
8

4
.2
1
0
2
4
.3
2
7

3
.5
8
8
2
4
.6
7
3

3
.1
4
4
2
3
.1
4
5

3
.0
3
5
G
E
L
g
ro
u
p
3
0
.6
1
0

4
.4
2
0
1
9
.0
7
5

3
.2
3
9
2
0
.5
5
0

4
.4
9
3
2
2
.7
0
5

4
.3
8
5
2
4
.8
8
5

4
.6
7
8
2
4
.8
7
5

4
.5
0
5
2
2
.9
3
2

4
.0
0
6
V
a
lu
e
s
a
re
e
xp
re
s
s
e
d
a
s
m
e
a
n

S
D
.
B
a
s
e
,
b
e
fo
re
th
e
o
p
e
ra
ti
o
n
;
B
e
fo
re
-C
P
B
,
b
e
fo
re
th
e
c
a
rd
io
p
u
lm
o
n
a
ry
b
y
p
a
s
s;
E
n
d
-C
P
B
,
a
t
th
e
e
n
d
o
f
c
a
rd
io
p
u
lm
o
n
a
ry
b
y
p
a
s
s;
1
h
-I
C
U
,
a
t
a
rr
iv
a
l
in
th
e
in
te
n
s
iv
e
c
a
re
u
n
it
;
6
h
-
IC
U
,
6
h
a
ft
e
r
s
u
rg
e
ry
;
2
4
h
-I
C
U
,
2
4
h
a
ft
e
r
s
u
rg
e
ry
;
a
n
d
4
8
h
-I
C
U
,
4
8
h
a
ft
e
r
s
u
rg
e
ry
;
R
L
,
R
in
g
e
r’
s
la
c
ta
te
p
ri
m
e
;
G
E
L
,
g
e
la
ti
n
p
ri
m
e
.
E. Tamayo et al.
1208
with regard to the total volume of fluid adminis-
tered during the intra-operative (Table 1) and post-
operative period (Table 4). The PaO2/FIO2 ratio in
the colloid group was significantly lower
(P5 0.032) as compared with the crystalloid group
48 h after arrival in the ICU. One patient in the RL
group had prolonged ventilation, while one of the
44 total patients had atrial fibrillation with fast
ventricular rate (120–180 bpm), requiring anti-
arrhythmic therapy.
Levels of plasma cytokines
Repeated-measures ANOVA revealed that, within
each group, variations in the plasma levels of IL-6,
IL-8, and TNF-a compared with baseline values
were significant over time. Compared with the
initial levels (base), IL-6 levels peaked at 6 h after
surgery (Po0.0001), showing a continuous de-
crease in the first 48 h after surgery (Fig. 1A). IL-8
levels underwent a similar trend in both groups,
peaking at 1 h after arrival in the ICU (Po0.0001)
and a progressive return towards the baseline
value 48 h after surgery (Fig. 1B). TNF-a levels
increased progressively in both groups to reach a
peak at 4 h after surgery in the RL group
(Po0.0001) and 6 h after surgery in the GEL group
(Po0.0001), with a slight return towards baseline
values at 48 h after surgery (Fig. 1C). However,
when analysed by repeated-measures ANOVA, no
significant difference was found between the
groups in IL-6, IL-8, and TNF-a plasma levels at
any time point.
Furthermore, no significant correlation was
found between cytokine plasma levels (IL-6, IL-8,
and TNF-a) and clinical postoperative variables
such as respiratory insufficiency, PaO2/FIO2 ratio,
extubation time, CK, CK-MB, need for inotropic
support, and length of stay in ICU in either group.
Plasma levels of CRP and complement (C4)
CRP levels increased in all patients, starting from
6 h in ICU and reaching maximum levels at 48 h
inICU (Po0.0001) (Fig. 2A). C4 levels decreased
significantly (Po0.0001) during the first minutes of
CPB, mainly because of haemodilution (Fig. 2B).
Thereafter, levels slightly increased, returning to
base values at 48 h-ICU (P5 0.425). Repeated mea-
sures of variance analysis (ANOVA) revealed these
differences were significant over time within
groups in the plasma level of CRP and C4, but no
significant differences were found between groups
at any sample point.
Discussion
This prospective, randomized study was designed
to examine any potential effect of priming the
extracorporeal circuit with crystalloid (RL) rather
Table 4
Postoperative course
Variable Total (n5 44) RL (n5 22) GEL (n5 22) P value
Death 0 0 0 N/A
Creatinine (mg/dl) 1.2  0.6 1.22  0.8 1.33  0.5 0.611
Respiratory insufficiency, [n (%)] 38 (86.4) 17 (77.3) 21 (95.5) 0.093
PaO2/FIO2 1h-ICU 269.8  82.2 273.8  97.1 265.7  66.1 0.749
PaO2/FIO2 6h-ICU 265.0  89.6 254.7  72.3 275.2  104.8 0.456
PaO2/FIO2 24 h-ICU 305.0  90.3 287.6  86.8 321.7  92.4 0.219
PaO2/FIO2 48 h-ICU 347.8  109.5 384.2  110.9 313.1  98.5 0.032*
Postoperative bleeding (ml/24 h) 971.8  510.9 946.0  537.9 995.0  496.6 0.760
Time to extubation (hrs) 12.8  17.7 11.9  19.4 13.7  16.2 0.829
Patients extubated at 24 h [n (%)] 42 (95.5) 21 (95.5) 21 (95.5) 0.742
Atrial fibrillation 1 0 1 N/A
CK (IU/l) 705.03  672.73 582.0  332.42 816.33  869.28 0.262
CK-MB (IU/l) 94.33  176.31 53.74  40.3 131.05  237.01 0.156
Need for blood transfusion [n (%)] 33 (75%) 17 (89.5%) 16 (94.1%) 0.412
Units donor blood 2  0.9 2.11  0.9 1.94  0.9 0.520
Fluid 0.9% NaCl (ml/24 h) 1179.1  97.6 1201.5  88.3 1156.7  103.2 0.129
Fluid gelatin (ml/24 h) 871.0  68.7 877.2  84.8 864.8  48.9 0.555
Fluid (ml/24 h) 2050.1  130.6 2078.7  142.1 2021.5  114.0 0.148
Need for inotropic support [n (%)] 20 (45.5) 8 (36.4) 12 (54.5) 0.225
Mean ICU stay (days) 2.3  2.0 2.10  1.8 2.64  2.2 0.388
Values are expressed as numbers (n), percentages (%), and mean  SD.
*Probability value of Po0.05 was considered to be significant.
RL, Ringer’s lactate prime; GEL, gelatin prime; CK, creatinine kinase; CK-MB, MB isoenzyme creatine kinase; ICU, intensive care unit.
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than colloid (gelatin) on post-surgical inflamma-
tory response. The two groups analysed were
homogeneous as far as demographic and clinical
data are concerned, and the sample size was
sufficient for comparing the two groups. We did
not detect any differences in the inflammatory
response (serum levels of the pro-inflammatory
cytokines IL-6, IL-8, and TNF-a; levels of C4, CRP,
and leukocytes) or any relevant adverse effects
(such as arrhythmia, respiratory insufficiency,
etc.) during or after the bypass cardiopulmonary
procedure (up to 48 h post procedure).
The onset of CPB was associated with an intense
SIRS, characterized by the activation of comple-
ment, neutrophils, endotoxin, elastases, and the
pro-inflammatory cytokines.14–16 The present study
confirms3,6,8,14 that on altering the CPB, there is an
intense SIRS accompanied by high levels of the
common pro-inflammatory cytokines (TNF-a, IL-6,
and IL-8), CRP, C4, and leukocytes.
Colloid-containing priming solutions are advo-
cated to prevent the initial decrease in colloid
osmotic pressure at the beginning of CPB,8,17 and
the clinical benefits of a normal colloid osmotic
pressure include reduced fluid administration, im-
proved postoperative patient recovery, and a shor-
tened postoperative hospital stay.8 In further
support of colloid solution use in CPB purging,
neutrophil and complement activation have been
shown to be reduced with colloid use,4–7 as well as
a reduction in plasma water, thus lowering the
inflammatory response.
According to the results of this study, however,
this hypothesis has not been confirmed, as the
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Fig. 1. Temporal profile of cytokines. Median plasma levels of (A)
interleukin IL-6, (B) IL-8, and (C) tumor necrosis factor (TNF-a)
in patients treated with Ringer’s lactate (RL) prime (light bars) or
gelatin (GEL) prime (dark bars) at different sampling times. Base,
before the operation; Before-CPB, before the cardiopulmonary
bypass; End-CPB, at the end of cardiopulmonary bypass; 1 h-
ICU, at arrival in the intensive care unit; 6 h-ICU, 6 h after
surgery; 24 h-ICU, 24 h after surgery; and 48 h-ICU, 48 h after
surgery. Data represent the median and interquartile range.
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Fig. 2. Temporal profile of C–reactive protein (A) and complement
(B). Median plasma levels in patients treated with Ringer’s lactate
(RL) prime (light bars) or gelatin (GEL) prime (dark bars) at
different sampling times. Base, before the operation; Before-CPB,
before the cardiopulmonary bypass; End-CPB, at the end of
cardiopulmonary bypass; 1 h-ICU, at arrival in the intensive
care unit; 6 h-ICU, 6 h after surgery; 24 h-ICU, 24 h after surgery;
and 48 h-ICU, 48 h after surgery. Data represent the median and
interquartile range.
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pattern of changes in the blood levels of cytokines,
CRP, and complement was similar in both the
group that used GEL and the group that used RL
for priming the CPB. A previous study that eval-
uated the efficacy of CPB, using either GEL prim-
ing (1650 ml) or RL priming (1650 ml), showed that
maintaining a normal colloid osmotic pressure
during CPB can be established by adding GEL to
the priming solution of an extracorporeal circuit
with a small prime volume.8 Similar increments in
TNF-a, complement, and neutrophil elastase were
found in both groups as indicators of SIRS.
In this study we have evaluated gelatin, a colloid
used in our centre for priming the CPB. Gelatin is
derived from bovine collagen, and the animal
peptide nature of gelatin may confer an enhanced
immunogenicity compared with other solution
fluids (hydroxyethyl starch, Ringer’s solution). Re-
cent studies demonstrate that the use of gelatin
solutions as volume replacement regimens in both
animals18 and the elderly undergoing major ab-
dominal surgery is associated with a significant
and marked increase in IL-6 and TNF-a as com-
pared with the use of Ringer’s or 4% hydroxyethyl
starch solutions.19,20 In our study, the lack of any
observed differences in the levels of cytokines,
CRP, and complement between colloid and crystal-
loid priming of the CPB may be due to the greater
intensity of the surgical trauma and/or CPB’s
liberation of cytokines during cardiac surgery,21
so that the effect of the purging liquids, whether
colloid or crystalloid, is minimized and masked by
these other factors.
Recent studies demonstrate that maintenance of
cardiovascular stability and effective organ perfu-
sion with fluid solutions is associated with an
attenuation of the inflammatory response.22,23 Be-
cause of relatively slow degradation of the gelatin-
based colloid, the volume expanding effect is
maintained for 2–3 h, while the volume expanding
effect of crystalloids (Ringer) is markedly shorter.
Gelatin-based colloid has been considered to be
effective in improving haemodynamics, the per-
ipheral perfusion, and the optimization of the
patient’s intravascular volume status.18 Conse-
quently, one could suppose that differences in
inflammatory response are related to the degree
of intravascular volume (which depends on the
type of plasma expander used). Nevertheless, no
differences were observed between the two groups
in our study. To avoid any distortion of the results,
one of the aims was to maintain a MAP (65–
80 mmHg) throughout the entire period of study
in both groups. The absence of significant changes
in pro-inflammatory cytokines and CRP between
the two groups of patients was also reinforced by
the absence of significant modifications in haemo-
dynamic and peri-operative variables. Three clini-
cally available parameters (blood pressure,
haematocrit, and CVP) were also used to test the
effectiveness of volume expansion with different
fluids. The results generally demonstrated equal
efficacy for both fluids on adequate perfusion.
Haematocrit, haemoglobin, and albumin decreased
after beginning CPB as a consequence of the effect
of haemodilution with clear priming solutions.
From a clinical point of view, CPB has been
associated with a large variety of clinical symp-
toms,1 and the extent of their intensity has been
correlated with the levels of cytokines and comple-
ment, and the severity of the SIRS.2–4 However, we
were not able to find a significant correlation
between plasma levels (IL-6, IL-8, and TNF-a)
and peri-operative variables. As for the presence
of relevant adverse effects related with postpump
syndromes (respiratory insufficiency, levels of
CPK-MB, need for inotropic support, units of
donor blood, need for blood transfusion etc.), there
were no differences between the two groups.
Chello et al.24 did not find any correlation between
the levels of cytokines and the adverse effects.
The conclusions from these results, however,
may be limited because (i) it is probable that the
sample size of the present study is not sufficient to
assess clinical outcomes such as intubation time,
length of stay in ICU, and postoperative pulmon-
ary morbidity, which are low in our patients, and
(ii) it is also possible that the sample size is not
sufficient to establish any correlation between the
levels of cytokines and pre- and postoperative
variables. Furthermore, to both groups we have
administered aprotinin, which is known to have
anti-inflammatory properties.2
Our study provides no significant clinical ad-
vantages for colloid priming as compared with
crystalloid priming: the blood levels of cytokines,
CRP, and complement and leucocytes, and the
haemodynamic and clinical profiles were similar.
Thus, as colloid use increases the costs and does
not bring any advantages, we believe that its
routine use is not justified in coronary artery
bypass grafting.
To conclude, on the basis of our data we can
affirm that priming with colloid as opposed to
crystalloid in patients undergoing coronary artery
bypass grafting with CPB produces no significant
Inflammatory responses to priming
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differences in the inflammatory response as mea-
sured by the levels of IL-6, IL-8, TNF-a, CRP, and
C4. On the basis of these data, we recommend the
routine use of crystalloids for priming the CPB.
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